Moleculin receives European Medicines Agency approval

Moleculin secures EMA approval to expand acute myeloid leukaemia trial across EU - Pharmafile

Moleculin Biotech has received approval from the European Medicines Agency (EMA) to expand its phase 3 ‘MIRACLE’ trial into nine additional EU countries — a key milestone in the development of its acute myeloid leukaemia (AML) treatment. The approval allows the company to proceed with its Clinical Trial Application (CTA) for the MIRACLE study, which […] The post Moleculin secures EMA approval to expand acute myeloid leukaemia trial across EU app…

Moleculin receives European Medicines Agency approval

Moleculin Biotech, a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, has announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application.